10.1002/ejoc.201701307
European Journal of Organic Chemistry
FULL PAPER
(3R,4R,5R)-tert-Butyl
2-benzyl-4-(hydroxymethyl)-3,5-dimethyl
(3R,4R,5R)-Ethyl
2-benzyl-5-ethyl-4-(hydroxymethyl)-3-methyl
isoxazolidine-3-carboxylate 8cA
isoxazolidine-3-carboxylate 8aB
Protocol B: 3cA (0.078 mmol, exo:endo = 98:2). Purification by column
chromatography (cyclohexane/ EtOAc = 8:2) gave white powder (20 mg,
87%), Rf = 0. 5 (cyclohexane/ EtOAc = 6:4). IR (NaCl) ν = 3443, 2975,
2929, 1719, 1455, 1369, 1138, 734 cm-1. 1H NMR (400 MHz, CDCl3 ) δ =
1.33 (d, 3H, J = 6.1 Hz), 1.40 (s, 3H), 1.52 (s, 9H), 2.45 (br s,1H), 2.79
(dt, 1H, J = 6.3 Hz, 7.2 Hz), 3.69 (m, 1H), 3.82 (m, 2H), 3.92 (d, 1H, J =
Protocol B: 3aB (0.028 mmol, exo:endo = 95:5). Purification by column
chromatography (cyclohexane/ EtOAc = 8:2) gave colorless oil (5 mg,
63%), Rf = 0.22 (cyclohexane/ EtOAc = 7:3). IR (NaCl) ν = 3433, 2926,
1726, 1455, 1260, 1023, 803, 698 cm-1. 1H NMR (400 MHz, CDCl3) δ =
0.91 (t, 3H, J = 7.5 Hz), 1.31 (t, 3H, J = 7.1 Hz), 1.47 (s, 3H), 1.62 (m,
1H), 1.73 (m, 1H), 2.34 (br s, 1H), 2.89 (ddd, 1H, J = 5.3 Hz, 6.2 Hz, 7.6
Hz), 3.62 (dd, 1H, J = 6.0 Hz, 13.1 Hz), 3.77 (m, 2H), 3.92 (d, 1H, J =
14.6 Hz), 4.03 (d, 1H, J = 14.6 Hz), 4.23 (m, 2H), 7.21 – 7.38 (m, 5H, H-
arom) ppm. 13C NMR (100 MHz, CDCl3) δ = 10.5, 14.1, 14.2, 27.5, 55.1,
55.5, 61.5, 61.8, 71.5, 80.5, 126.9, 128.2, 128.3, 138.5, 173.2 ppm.
14.7 Hz), 4.05 (d, 1H, J = 14.7 Hz), 7.21 -7.38 (m, 5H, H-arom) ppm. 13
C
NMR (100 MHz, CDCl3) δ = 14.6, 19.8, 28.1, 55.1, 56.8, 61.6, 71.9, 75.6,
82.4, 126.9, 128.1, 128.2, 138.7, 172.4 ppm. HRMS: (ESI) m/z: calcd for
C18H28NNaO4 [M+Na]+: 344.1832, found 344.1847. Enantioselectivity
was determined by chiral HPLC analysis, CHIRALPAK AS-H, isooctane/i-
PrOH = 98:2, 1 mL/min, 254 nm; tR (min): 13.4 (minor) and 20.9 (major)
with 96% ee for exo and dr: 98:2.
HRMS: (ESI) m/z
:
calcd for C17H26NO4 [M+H]+: 308.1856,
found 308.1864. Enantioselectivity was determined by chiral HPLC
analysis, CHIRALPAK AS-H, isooctane/i-PrOH = 98:2, 1 mL/min, 211
nm; tR (min): 22.2 (minor) and 27.4 (major) with 56% ee for exo and dr:
78:22.
(3R,4R,5R)-Ethyl 2-benzyl-3-ethyl-5-methyl-4-((E)-((S)-1-phenylethyl
imino) methyl) isoxazolidine-3-carboxylate 7dA
According the protocol A, but this reaction was stirred in chloroform on a
silver foil. 1H NMR (400 MHz, CDCl3) δ = 0.93 (t, 3H, J = 7.4 Hz), 1.29 (d,
3H, J = 6.2 Hz), 1.35 (t, 3H, J = 7.1 Hz), 1.51 (d, 3H, J = 6.6 Hz), 1.65 (m,
1H), 1.94 (m, 1H), 3.65 (dd, 1H, J = 5.5 Hz, 7.6 Hz), 3.76 (d, 1H, J = 15.0
Hz), 4.08 (m, 2H), 4.28 (m, 2H), 4.39 (q, 1H, J = 6.6 Hz), 7.21 – 7.37 (m,
10H, H-arom), 7.87 (d, 1H, J = 7.6 Hz) ppm. HRMS: (ESI) m/z : calcd
for C25H33N2O3 [M+H]+: 409.2486, found 409.2469.The enantiomeric
excess was determined by 1H NMR, based on H12 (0.93 ppm) major and
(0.63 ppm) minor with 92% ee and dr: 96:4.
(3R,4R,5R)-Ethyl
isoxazolidine-3-carboxylate 8aC
2-benzyl-4-(hydroxymethyl)-3-methyl-5-propyl
Protocol B: 3aC (0.093 mmol, exo:endo = 97:3) Purification by column
chromatography (cyclohexane/ EtOAc = 8:2) gave yellow oil (23 mg,
77%), Rf = 0.27 (cyclohexane/ EtOAc = 7:3). IR (NaCl) ν = 3448, 2957,
2931, 2872, 1726, 1455, 1143, 1024, 698 cm-1. 1H NMR (400 MHz,
CDCl3) δ = 0.88 (t, 3H, J = 7.3 Hz), 1.31 (t, 3H, J = 7.1 Hz), 1.34 (m, 2H),
1.45 (s, 3H), 1.55 (m, 1H), 1.72 (m, 1H), 2.39 (br s, 1H), 2.87 (ddd, 1H, J
= 5.4 Hz, 6.3 Hz, 7.5 Hz), 3.72 (m, 3H), 3.92 (d, 1H, J = 14.6 Hz), 4.01 (d,
1H, J = 14.7 Hz), 4.22 (m, 2H), 7.21 – 7.37 (m, 5H, H-arom) ppm. 13C
NMR (100 MHz, CDCl3) δ = 14.1, 14.2, 19.5, 36.7, 55.1, 55.8, 61.5, 61.7,
71.4, 79.1, 126.9, 128.1, 128.3, 138.4, 173.2 ppm. HRMS: (ESI) m/z:
(3R,4R,5R)-Methyl
2-benzyl-4-(hydroxymethyl)-5-methyl-3-propyl
isoxazolidine-3-carboxylate 8eA
Protocol B: 3eA (0,024 mmol, exo:endo = 100:0). Purification by column
chromatography (cyclohexane/ EtOAc = 9:1) gave colorless oil (6 mg,
74%), Rf = 0. 27 (cyclohexane/ EtOAc = 7:3). IR (NaCl) ν = 3447, 2962,
2876, 1732, 1454, 1214, 1082, 735 cm-1. 1H NMR (400 MHz, CDCl3) δ =
0.97 (t, 3H, J = 7.3 Hz), 1.32 (d, 3H, J = 6.3 Hz), 1.35 (m, 2H), 1.71 (m,
1H), 1.83 (m,1H), 2.66 (br s, 1H), 2.94 (dd, 1H, J = 4.7 Hz, 9.9 Hz), 3.80
(s, 4H), 3.86 (m, 2H), 4.15 (m, 2H), 7.23-7.34 (m, 5H, H-arom) ppm. 13C
NMR (100 MHz, CDCl3) δ = 14.6, 18.7, 18.8, 32.2, 51.8, 53.3, 55.0, 62.1,
76.0, 76.1, 127.0, 128.1, 128.3, 138.5, 172.5 ppm. HRMS: (ESI) m/z :
calcd
for C18H28NO4
[M+H]+:
322.2013,
found
322.2018.
Enantioselectivity was determined by chiral HPLC analysis, CHIRALPAK
AS-H, isooctane/i-PrOH = 98:2, 1 mL/min, 211 nm; tR (min): 18.7 (minor)
and 21.5 (major) with 88% ee for exo obtained by Catalyst II with dr =
94:6; tR (min): 18.8 (minor) 21.5 (major) with 54% ee for exo obtained by
Catalyst I with dr: 78:22.
(3R,4R,5S)-Ethyl
isoxazolidine-3-carboxylate 8aE
5-acetoxy-2-benzyl-4-(hydroxymethyl)-3-methyl
calcd for
C17H25NNaO4 [M+Na]+: 330.1676, found 330.1684.
Protocol B: 3aE (0.048 mmol, exo:endo = 85:15). Purification by column
chromatography (cyclohexane/ EtOAc = 7:3) gave colorless oil (13 mg,
73%), Rf = 0.25 (cyclohexane/ EtOAc = 5:5). IR (NaCl) ν = 3520, 2935,
1734, 1239, 1039, 698 cm-1. 1H NMR (400 MHz, CDCl3) δ = 1.31 (t, 3H, J
= 7.1 Hz), 1.42 (s, 3H), 2.03 (s, 3H), 2.28 (br s, 1H), 2.94 (m, 1H), 3.75
(m, 1H), 3.86 (m, 1H), 3.92 (d, 1H,J = 14.6 Hz), 3.96 (m, 1H), 4.02 (d, 1H,
J = 14.6 Hz), 4.23 (m, 4H), 7.22 – 7.37 (m, 5H, H-arom) ppm. 13C NMR
(100 MHz, CDCl3) δ = 13.4, 14.1, 20.8, 53.4, 54.9, 61.5, 61.7, 65.7, 70.9,
77.6, 127.0, 128.1, 128.2, 137.9, 171.1, 171.3 ppm. HRMS: (ESI) m/z :
calcd for C18H25NNaO6 [M+Na]+: 374.1574, found 374.1580.
Enantioselectivity was determined by chiral HPLC analysis, Lux-5µ-
Cellulose II, isooctane/i-PrOH = 90:10, 1 mL/min, 211 nm; tR (min): 23.9
(minor) and 30.3 (major) with 82% ee for exo obtained by Catalyst II with
dr: 91:9; tR (min): 24 (minor) and 30 (major) with 76% ee for exo obtained
by Catalyst I with dr: 88:12.
Enantioselectivity was determined by chiral HPLC analysis, CHIRALCEL
OD, isooctane/i-PrOH = 98:2, 1 mL/min, 254 nm; tR (min): 15.9 (major)
and 18.6 (minor) with 90% ee for exo and dr: 95:5.
(3R,4R,5R)-Ethyl
2,3,5-trimethyl-4-((E)-((S)-1-phenylethylimino)
methyl) isoxazolidine-3-carboxylate 7fA
According the protocol A, the product obtained is colorless oil. 1H NMR
(400 MHz, C6D6) δ = 0.91 (t, 3H), 1.23 (d, 3H), 1.37 (m, 6H), 2.64 (s, 3H),
3.69 (m, 1H), 3.92 (m, 2H), 4.12 (m,1H), 4.44 (m, 1H), 7.08 -7.58 (m, 6H,
H-arom, 1H). HRMS: (ESI) m/z: calcd for C18H26N2NaO3 [M+Na]+:
341.1836, found 341.1847. The enantiomeric excess was determined by
1H NMR, based on H5 (4.44 ppm) major and (4.53 ppm) minor with 92%
ee and dr: 96:4.
(3R,4R,5R)-Methyl
2,3,5-trimethyl-4-((E)-((S)-phenylethylimino)
methyl) isoxazolidine-3-carboxylate 7gA
(3R,4R,5S)-Ethyl
5-(2-acetoxyethyl)-2-benzyl-4-(hydroxymethyl)-3-
According the protocol A, the product obtained is colorless oil. 1H NMR
(400 MHz, CDCl3) δ = 1.27 (s, 3H), 1.34 (d, 3H, J = 5.8 Hz), 1.49 (d, 3H,
J = 6.7 Hz), 2.62 (s, 3H), 3.46 (dd, 1H, J =6.4 Hz, J = 6.4 Hz), 3.76 (s,
3H), 4.32 (m, 1H), 4.37 (q, 1H, J = 6.7 Hz), 7.2 -7,4 (m, 5H, H-arom),
7.76 (d, 1H, J = 61 Hz). The enantiomeric excess was determined by 1H
NMR, based on MeO (3.76 ppm) major and (3.74 ppm) minor with 92%
ee and dr: 96:4.
methyl isoxazolidine-3-carboxylate 8aF
Protocol B: 3aF (0.16 mmol, exo:endo = 89:11). Purification by column
chromatography (cyclohexane/ EtOAc = 7:3) gave colorless oil (38 mg,
65%), Rf = 0.37 (cyclohexane/ EtOAc = 5:5). IR (NaCl) ν = 3520, 2935,
1734, 1239, 1039, 698 cm-1. 1H NMR (400 MHz, CDCl3) δ = 1.29 (t, 3H, J
= 7.3 Hz), 1.45 (s, 3H), 1.90 – 2.10 (m, 2H), 1.98 (s, 3H), 2.21 (br s, 1H),
2.92 (q, 1H, J = 6.1 Hz), 3.74 (m, 1H), 3.83 (m, 2H), 3.90 (d, 1H,J = 14.3
Hz), 3.98 (d, 1H, J = 14.3 Hz), 4.00 – 4.20 (m, 2H) 4.25 (m, 4H), 7.22 –
This article is protected by copyright. All rights reserved.